Tuberous sclerosis protein 2 (TSC2) modulates CCN4 cytoprotection during apoptotic amyloid toxicity in microglia

Current Neurovascular Research

Volumn 10, Issue 1, 2013, Pages 29-38

  Shang, Yan Chen ^a,c   Chong, Zhao Zhong ^a,c   Wang, Shaohui ^a,c   Maiese, Kenneth ^a,b,c  

^a New Jersey Medical School University Hospital Cancer Center   (United States)

^b RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^c New Jersey Health Sciences University   (United States)

Author keywords

Akt; Alzheimer's disease; Amyloid; CCN4; Microglia; MTOR; P70S6K; PI 3 k; TSC2; Tuberin; WISP1

Indexed keywords

AMYLOID; CELL NUCLEUS DNA; CYTOCHROME C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; PHOSPHATIDYLSERINE; PROTEIN KINASE B; REGULATOR PROTEIN; S6 KINASE; TUBEROUS SCLEROSIS PROTEIN 2; UNCLASSIFIED DRUG; WNT1 INDUCIBLE SIGNALING PATHWAY PROTEIN 1;

APOPTOSIS; ARTICLE; CONTROLLED STUDY; DNA DEGRADATION; ENZYME PHOSPHORYLATION; ENZYME REGULATION; MICROGLIA; NEUROPROTECTION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING;

EID: 84873052754     PISSN: 15672026     EISSN: 18755739     Source Type: Journal    
DOI: 10.2174/156720213804806007     Document Type: Article

References (56)

1. Bajda M, Guzior N, Ignasik M, Malawska B. Multi-target-directed ligands in Alzheimer's disease treatment. Curr Med Chem. 2011 Nov 1;18(32):4949-75.
2. Maiese K, Chong ZZ, Hou J, Shang YC. New strategies for Alzheimer's disease and cognitive impairment. Oxid Med Cell Longev. 2009 Nov-Dec;2(5):279-89.
3. Delrieu J, Ousset PJ, Vellas B. Gantenerumab for the treatment of Alzheimer's disease. Expert Opin Biol Ther. 2012 May 15.
4. Yeger H, Perbal B. The CCN family of genes: a perspective on CCN biology and therapeutic potential. J Cell Commun Signal. 2007 Dec;1(3-4):159-64.
5. French DM, Kaul RJ, D'Souza AL, Crowley CW, Bao M, Frantz GD, et al. WISP-1 is an osteoblastic regulator expressed during skeletal development and fracture repair. Am J Pathol. 2004 Sep;165(3):855-67.
6. Hennemeier I, Humpf HU, Gekle M, Schwerdt G. The food contaminant and nephrotoxin ochratoxin A enhances Wnt1 inducible signaling protein 1 and tumor necrosis factor-alpha expression in human primary proximal tubule cells. Molecular nutrition & food research. 2012 Sep;56(9):1375-84.
7. Su F, Overholtzer M, Besser D, Levine AJ. WISP-1 attenuates p53- mediated apoptosis in response to DNA damage through activation of the Akt kinase. Genes Dev. 2002 Jan 1;16(1):46-57.
8. Venkatesan B, Prabhu SD, Venkatachalam K, Mummidi S, Valente AJ, Clark RA, et al. WNT1-inducible signaling pathway protein-1activates diverse cell survival pathways and blocks doxorubicininduced cardiomyocyte death. Cell Signal. 2010 May;22(5):809-20.
9. Heise RL, Stober V, Cheluvaraju C, Hollingsworth JW, Garantziotis S. Mechanical stretch induces epithelial-mesenchymal transition in alveolar epithelia via hyaluronan activation of innate immunity. J Biol Chem. 2011 May 20;286(20):17435-44.
10. Wang S, Chong ZZ, Shang YC, Maiese K. Wnt1 inducible signaling pathway protein 1 (WISP1) blocks neurodegeneration through phosphoinositide 3 kinase/Akt1 and apoptotic mitochondrial signaling involving Bad, Bax, Bim, and Bcl-xL. Curr Neurovasc Res. 2012 Feb;9(1):20-31.
11. Wang S, Chong ZZ, Shang YC, Maiese K. WISP1 (CCN4) autoregulates its expression and nuclear trafficking of beta-catenin during oxidant stress with limited effects upon neuronal autophagy. Curr Neurovasc Res. 2012 Apr 4;9(2):89-99.
12. Wang S, Chong ZZ, Shang YC, Maiese K. WISP1 neuroprotection requires FoxO3a post-translational modulation with autoregulatory control of SIRT1. Curr Neurovasc Res. 2012 Nov 12;(in press).
13. Shang YC, Chong ZZ, Wang S, Maiese K. WNT1 Inducible Signaling Pathway Protein 1 (WISP1) Targets PRAS40 to Govern beta-Amyloid Apoptotic Injury of Microglia. Curr Neurovasc Res. 2012 Aug 6;9(4):239-49.
14. Bach JP, Mengel D, Wahle T, Kautz A, Balzer-Geldsetzer M, Al- Abed Y, et al. The Role of CNI-1493 in the Function of Primary Microglia with Respect to Amyloid-beta. J Alzheimers Dis. 2011 Jan 1;26(1):69-80.
15. Fuhrmann M, Bittner T, Jung CK, Burgold S, Page RM, Mitteregger G, et al. Microglial Cx3cr1 knockout prevents neuron loss in a mouse model of Alzheimer's disease. Nat Neurosci. 2010 Mar 21.
16. Rogers J, Lue LF. Microglial chemotaxis, activation, and phagocytosis of amyloid beta-peptide as linked phenomena in Alzheimer's disease. Neurochem Int. 2001 Nov-Dec;39(5-6):333- 40.
17. Salminen A, Kaarniranta K. Siglec receptors and hiding plaques in Alzheimer's disease. J Mol Med. 2009 Jul;87(7):697-701.
18. Shang YC, Chong ZZ, Hou J, Maiese K. The forkhead transcription factor FoxO3a controls microglial inflammatory activation and eventual apoptotic injury through caspase 3. Curr Neurovasc Res. 2009 Feb;6(1):20-31.
19. Shang YC, Chong ZZ, Wang S, Maiese K. Prevention of betaamyloid degeneration of microglia by erythropoietin depends on Wnt1, the PI 3-K/mTOR pathway, Bad, and Bcl-xL. Aging (Albany NY). 2012 Mar 3;4(3):187-201.
20. Colston JT, de la Rosa SD, Koehler M, Gonzales K, Mestril R, Freeman GL, et al. Wnt-induced secreted protein-1 is a prohypertrophic and profibrotic growth factor. Am J Physiol Heart Circ Physiol. 2007 Sep;293(3):H1839-46.
21. Reddy VS, Valente AJ, Delafontaine P, Chandrasekar B. Interleukin-18/WNT1-inducible signaling pathway protein-1 signaling mediates human saphenous vein smooth muscle cell proliferation. J Cell Physiol. 2011 Dec;226(12):3303-15.
22. Chong ZZ, Shang YC, Wang S, Maiese K. A Critical Kinase Cascade in Neurological Disorders: PI 3-K, Akt, and mTOR. Future Neurol. 2012;7(6):733-48.
23. Maiese K, Chong ZZ, Wang S, Shang YC. Oxidant Stress and Signal Transduction in the Nervous System with the PI 3-K, Akt, and mTOR Cascade. International journal of molecular sciences. 2012;13(11):13830-66.
24. Chong ZZ, Maiese K. Mammalian Target of Rapamycin Signaling in Diabetic Cardiovascular Disease. Cardiovasc Diabetol. 2012;11(1):45.
25. Chong ZZ, Shang YC, Maiese K. Cardiovascular Disease and mTOR Signaling. Trends Cardiovasc Med. 2011;21(5):151-5.
26. Inoki K, Li Y, Zhu T, Wu J, Guan KL. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat Cell Biol. 2002;4(9):648-57.
27. Manning BD, Tee AR, Logsdon MN, Blenis J, Cantley LC. Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3- kinase/akt pathway. Mol Cell. 2002;10(1):151-62.
28. Potter CJ, Pedraza LG, Xu T. Akt regulates growth by directly phosphorylating Tsc2. Nat Cell Biol. 2002;4(9):658-65.
29. Inoki K, Zhu T, Guan KL. TSC2 mediates cellular energy response to control cell growth and survival. Cell. 2003 26;115(5):577-90.
30. Sofer A, Lei K, Johannessen CM, Ellisen LW. Regulation of mTOR and cell growth in response to energy stress by REDD1. Mol Cell Biol. 2005;25(14):5834-45.
31. Chong ZZ, Li F, Maiese K. Erythropoietin requires NF-kappaB and its nuclear translocation to prevent early and late apoptotic neuronal injury during beta-amyloid toxicity. Curr Neurovasc Res. 2005;2(5):387-99.
32. Chong ZZ, Li F, Maiese K. Cellular demise and inflammatory microglial activation during beta-amyloid toxicity are governed by Wnt1 and canonical signaling pathways. Cell Signal. 2007;19(6):1150-62.
33. Chong ZZ, Kang JQ, Maiese K. Erythropoietin is a novel vascular protectant through activation of Akt1 and mitochondrial modulation of cysteine proteases. Circulation. 2002;106(23):2973- 9.
34. Chong ZZ, Kang JQ, Maiese K. Erythropoietin fosters both intrinsic and extrinsic neuronal protection through modulation of microglia, Akt1, Bad, and caspase-mediated pathways. Br J Pharmacol. 2003;138(6):1107-18.
35. Hou J, Chong ZZ, Shang YC, Maiese K. Early apoptotic vascular signaling is determined by Sirt1 through nuclear shuttling, forkhead trafficking, bad, and mitochondrial caspase activation. Curr Neurovasc Res. 2010;7(2):95-112.
36. Hou J, Wang S, Shang YC, Chong ZZ, Maiese K. Erythropoietin Employs Cell Longevity Pathways of SIRT1 to Foster Endothelial Vascular Integrity During Oxidant Stress. Curr Neurovasc Res. 2011;8(3):220-35.
37. Shang YC, Chong ZZ, Hou J, Maiese K. Wnt1, FoxO3a, and NFkappaB oversee microglial integrity and activation during oxidant stress. Cell Signal. 2010;22(9):1317-29.
38. Hou J, Chong ZZ, Shang YC, Maiese K. FoxO3a governs early and late apoptotic endothelial programs during elevated glucose through mitochondrial and caspase signaling. Mol Cell Endocrinol. 2010;321(2):194-206.
39. Shang YC, Chong ZZ, Wang S, Maiese K. Erythropoietin and Wnt1 Govern Pathways of mTOR, Apaf-1, and XIAP in Inflammatory Microglia. Curr Neurovasc Res. 2011;8(4):270-85.
40. Pearson RB, Dennis PB, Han JW, Williamson NA, Kozma SC, Wettenhall RE, et al. The principal target of rapamycin-induced p70s6k inactivation is a novel phosphorylation site within a conserved hydrophobic domain. Embo J. 1995;14(21):5279-87.
41. Chong ZZ, Shang YC, Wang S, Maiese K. Shedding new light on neurodegenerative diseases through the mammalian target of rapamycin. Prog Neurobiol. 2012;99(2):128-48.
42. Gwinn DM, Shackelford DB, Egan DF, Mihaylova MM, Mery A, Vasquez DS, et al. AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol Cell. 2008;30(2):214-26.
43. Ng S, Wu YT, Chen B, Zhou J, Shen HM. Impaired autophagy due to constitutive mTOR activation sensitizes TSC2-null cells to cell death under stress. Autophagy. 2011;7(10):1173-86.
44. Reith RM, Way S, McKenna J, Haines K, Gambello MJ. Loss of the tuberous sclerosis complex protein tuberin causes Purkinje cell degeneration. Neurobiol Dis. 2011;43(1):113-22.
45. Chong ZZ, Li F, Maiese K. Oxidative stress in the brain: Novel cellular targets that govern survival during neurodegenerative disease. Prog Neurobiol. 2005;75(3):207-46.
46. Maiese K, Chong ZZ, Shang YC. OutFOXOing disease and disability: the therapeutic potential of targeting FoxO proteins. Trends Mol Med. 2008;14(5):219-27.
47. Maiese K, Chong ZZ, Shang YC, Wang S. Targeting disease through novel pathways of apoptosis and autophagy. Expert opinion on therapeutic targets. 2012;(in press).
48. Bailey TJ, Fossum SL, Fimbel SM, Montgomery JE, Hyde DR. The inhibitor of phagocytosis, O-phospho-L-serine, suppresses Muller glia proliferation and cone cell regeneration in the lightdamaged zebrafish retina. Exp Eye Res. 2010;91(5):601-12.
49. Schutters K, Reutelingsperger C. Phosphatidylserine targeting for diagnosis and treatment of human diseases. Apoptosis. 2010;15(9):1072-82.
50. Koh PO. Nicotinamide attenuates the decrease of astrocytic phosphoprotein PEA-15 in focal cerebral ischemic injury. J Vet Med Sci. 2012;74(3):377-80.
51. Maiese K, Chong ZZ, Shang YC. "Sly as a FOXO": New paths with Forkhead signaling in the brain. Curr Neurovasc Res. 2007;4(4):295-302.
52. Favaloro B, Allocati N, Graziano V, Di Ilio C, De Laurenzi V. Role of Apoptosis in disease. Aging (Albany NY). 2012;4(5):330- 49.
53. Maiese K, Chong ZZ, Shang YC, Wang S. Novel directions for diabetes mellitus drug discovery. Expert opinion on drug discovery. 2012;(in press).
54. Spilman P, Podlutskaya N, Hart MJ, Debnath J, Gorostiza O, Bredesen D, et al. Inhibition of mTOR by rapamycin abolishes cognitive deficits and reduces amyloid-beta levels in a mouse model of Alzheimer's disease. PLoS One. 2010;5(4):e9979.
55. Di Nardo A, Kramvis I, Cho N, Sadowski A, Meikle L, Kwiatkowski DJ, et al. Tuberous sclerosis complex activity is required to control neuronal stress responses in an mTORdependent manner. J Neurosci. 2009;29(18):5926-37.
56. Gazitt Y, Kolaparthi V, Moncada K, Thomas C, Freeman J. Targeted therapy of human osteosarcoma with 17AAG or rapamycin: characterization of induced apoptosis and inhibition of mTOR and Akt/MAPK/Wnt pathways. Int J Oncol. 2009;34(2):551-61.